Press Releases
Vaccine attitudes detected in tweets by AI model
People’s attitudes towards vaccines can now be detected from their social media posts by an intelligent AI model, developed by researchers at the University of Warwick.
Reducing patients’ breathing efforts could be key to success of non-invasive respiratory support in COVID-19 patients
Working with an international team of leading intensive care clinicians, engineering researchers at the University of Warwick have used computational modelling to show that non-invasive respiratory support is more likely to be successful if it allows significant reductions in patients’ breathing efforts.
Reusable and customised facemask to keep healthcare workers safe thanks to digital supply-chain
Throughout the pandemic the filtering facepiece 3 respirator (FFP3) mask was heavily in demand, as it is the most widely used respiratory protective equipment in UK healthcare system. However, according to a study with health workers from 32 hospitals, the overall fit-testing pass rates had a mean pass rate of 81%.
Using digital flash glucose monitoring for people with diabetes & COVID-19 frees up NHS resources
People with diabetes are at a higher risk of poor outcomes and severe illness if they develop COVID-19, they need careful glucose monitoring to ensure appropriate glycaemic control during a period of any acute illness, including due to COVID-19. In order to support the management of these patients at UHCW, digital flash glucose monitoring devices were used as part of a a nationally leading research project. Researchers from WMG at the University of Warwick, and UHCW evaluated the benefits of this trailblazing research.
Giving a voice to new parents during the pandemic
A new UK-wide study is looking to give a voice to people who became parents for the first time during the pandemic, in order to learn how they can be best supported.
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the